This educational and promotional event is supported and funded by Flynn Pharma Ltd.
London Neurodevelopmental Disorders Study Day 2023
Dr Sudipta Sen is the clinical lead for Richmond Community Paediatric Medical Services and lead for under 5 years assessment of childhood autism in Richmond. With 28 years of experience as a paediatrician, specialising in neuro-disability, she has trained in ADOS, ADI, DISCO, Griffith’s developmental scale, PET 2 epilepsy and is a qualified sleep practitioner. She completed her DCH and MRCPCH in 2000 and has been elected as Fellow of the Royal College of Paediatrics and Child Health since 2018. She is a mentor, trainer and assessor for paediatricians aspiring to become consultants in the UK and works jointly with the GMC and RCPCH as a member of the CESR sub-committee. With a special interest in ADHD occurring with learning disabilities in children, Dr Sen regularly lectures in ADHD workshops and webinars for doctors, parents and the voluntary sector. She is a passionate advocate for nurturing neurodiversity and early assessment of diverse development as the key to providing growing children with the best outcomes for their future.
Dr Male is a Consultant Community Paediatrician and leads the local clinic and child development team. He has been working with Trust and local commissioners to develop a potential neurodevelopmental pathway. He leads the realist evaluation of autism service delivery funded by and working with the NHSE autism team. His research interests also include how we can use digitech to aid diagnosis and therapeutic intervention, for example using the Wii Fit in children with cerebral palsy, and access to sport for children with special needs.
With over 12 years’ experience as a paediatric/neonatal doctor in the NHS working in paediatric units, including neonatal intensive care units, Dr Datt has a specialist interest in neurology, rare paediatric diseases, and developmental clinics, with associated mental health disorders including Autism Spectrum Disorder (ASD), and Attention Deficit Hyperactivity Disorder (ADHD).
Dr Datt’s research interests include rare paediatric diseases such as Mucopolysaccharidoses (MPS), Paediatric Multiple Sclerosis, Haemophilia, Sickle Cell Anaemia, Beta-thalassaemia, X-Linked Hypophosphatemia (XLH), Vitamin D deficiency, Achondroplasia, Primary Immunodeficiencies (PID’s), and oncology (especially Astrocytoma and Neuroblastoma) in both small molecule therapeutics, biologics, and gene therapy.
As a postgraduate tutor and board of examiner with the Faculty of Pharmaceutical Medicine (FPM), Dr Datt is a revalidation appraiser on behalf of the Royal College of Physicians for FPM. His passion for delivering optimum client-focused care, extends as he continues to teach junior doctors, delivering medical education and raising awareness of rare paediatric conditions.
After completing a degree in Biological Medicinal Chemistry with Drug Design (BSc.), Dr Datt acquired a postgraduate diploma in Pharmaceutical Medicine from Oxford and graduated from Medical School (MBBS) from the University of East Anglia. He has also undertaken postgraduate certificates and diplomas in child health as well as conducting research in gastro-oesophageal reflux disease and leukaemia at the National Institute for Health (NIH) in Maryland, USA.
Dr McCloskey is a registered pharmacist of the General Pharmaceutical Council (GPhC) and Pharmaceutical Society in Northern Ireland (PSNI), and a fellow of the Royal Pharmaceutical Society with a range of experience working across the three main sectors of pharmacy clinical practice, academia, and industry. Upon successful completion of her pre-registration training Dr McCloskey returned to Queen's University Belfast and completed a PhD in pharmaceutics where she developed 'Self-assembled Peptide Nanomaterials for the Prevention of Biomaterial Infection'. This was followed by an industry-academia collaborative post-doc between the Royal College of Surgeons in Ireland (RCSI, Dublin) and the Galway-based nebuliser company Aerogen, a global leader in aerosol delivery. This work was also linked with a national patient focused medical device research centre, CURAM based at The National University of Ireland, Galway. Dr McCloskey is a member of the Royal Pharmaceutical Society and Fellow of Higher Education Academy. Links are maintained with clinical pharmacy through regular days in practice both in hospital and community settings.
Gaby is the research co-ordinator for the Paediatric Medicines Research Unit (PMRU) at Alder Hey Children’s NHS Foundation Trust. The unit’s research themes are drug safety, formulations and medicines optimisation. Gaby is a registered children’s nurse since 2006 working in neurology /neurosurgery. She became a research nurse in 2009 before moving into the role of PMRU research coordinator in 2019, supporting research design, development, delivery and governance. Her research interests include acceptability of medicines in children and young people.
Dr Carsten Vogt is a consultant child & adolescent psychiatrist and clinical lead for the ADHD Specialist CAMHS pathway at CYPF Berkshire. Dr Vogt has a special interest in the use of objective measurements for diagnostic assessment and measuring of treatment response in ADHD. He introduced the QbTest as part of the standard routine ADHD assessment in Berkshire in 2008 and published several papers on its clinical application. Dr Vogt has a particular interest in the effects of physical exercise on alleviating symptoms of ADHD and its consideration as a therapeutic intervention or adjunct with standard treatments for ADHD.
What will the webinar cover?
Key learning objectives
- To explore the findings of a single neurodevelopmental pathway for ASD or ADHD.
- To highlight the challenges of managing sleep in children with ASD and provide management strategies to improve outcomes.
- To outline the challenges of ADHD diagnosis and treatment.
- To explore the techniques and support available to help children with neurodevelopmental disorders swallow their medication.
- To identify different types of ADHD and understand the benefits of specific exercise to improve patient outcomes.